AUS
NZ
UK
CA
USA
IND
Highlights
- Orthocell OCC signs exclusive distribution agreement for Remplir™ in Singapore.
- First major international expansion for Remplir™ after regulatory approval in Singapore.
- Strong financial position with A$35 million in cash supports further growth.
Orthocell Ltd (ASX:OCC) has made a significant step in its global expansion strategy by securing a distribution agreement with Device Technologies Asia (DT Asia) to exclusively market and distribute its nerve repair device, Remplir™, in Singapore. This move marks the product’s first major international expansion beyond Australia and New Zealand, following recent regulatory approval from Singapore’s Health Sciences Authority. The expansion is particularly notable for its strategic alignment with the growing demand for advanced medical technologies in key regions, complementing broader trends in the ASX oil and gas sector, where growth is driven by innovation and global market opportunities.
Strategic Global Expansion
The agreement signals a key milestone for Orthocell as it expands into Singapore, a region recognized for its robust medical infrastructure and strategic positioning as a gateway to the ASEAN markets. The move aligns with the company's broader ambition to capture a share of the growing US$3.5 billion global nerve repair market. Initial sales of Remplir™ are projected to begin in Q1 2025, further expanding the device's footprint.
Partnership with Device Technologies Asia
DT Asia will be instrumental in promoting Remplir™ through its established relationships with plastic reconstructive and orthopaedic surgeons. With a strong expertise in medical marketing and education, DT Asia is expected to leverage its network to drive the adoption of the device in Singapore. The partnership builds on the success Orthocell has already experienced with Device Technologies in Australia and New Zealand, giving confidence in a similar outcome for the Singapore market.
Financial Strength Supporting Expansion
Orthocell remains well-funded, with A$35 million in cash and no debt, providing a solid financial base to support ongoing international growth. The company is also progressing regulatory approvals in other key regions, including the United States, Canada, and Europe, positioning itself for continued global expansion.
As the global nerve repair market expands, Orthocell’s strategic moves in Singapore, backed by strong partnerships and financial stability, put the company in a favorable position for future growth in international markets.
